Evidence map›Paper›PMID 32351898›Full record

ArticleFrontiers in oncology2020

A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients.

Marco Rastrelli, Paolo Del Fiore, Alessandra Buja, Antonella Vecchiato, Carlo Riccardo Rossi, Vanna Chiarion Sileni, Saveria Tropea, Francesco Russano, Manuel Zorzi, Romina Spina and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused byInternational journal of molecular sciences · 2022
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Marco RastrelliSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Paolo Del FioreSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Alessandra BujaDepartment of Cardiological, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Antonella VecchiatoSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Carlo Riccardo RossiSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Vanna Chiarion SileniMelanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Saveria TropeaSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Francesco RussanoSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Manuel ZorziVeneto Tumour Registry, Azienda Zero, Padua, Italy.
Romina SpinaSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Rocco CappellessoSurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Renzo MazzarottoDepartment of Surgery and Oncology, Unit of Radiotherapy, Hospital Trust of Verona, Verona, Italy.
Francesco CavallinIndependent Statistician, Solagna, Italy.
Franco BassettoClinic of Plastic Surgery, Department of Neuroscience, Padua University Hospital, University of Padua, Padua, Italy.
Elisabetta BezzonRadiology Unit, Department of Imaging and Medical Physics, Istituto Oncologico Veneto IOV IRCSS, Padua, Italy.
Beatrice FerrazziPostgraduate School of Occupational Medicine, University of Verona, Verona, Italy.
Mauro AlaibacUnit of Dermatology, University of Padua, Padua, Italy.
Simone MocellinSurgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Istituto Oncologico Veneto · ITUniversity of Padua · ITUniversity of Verona · ITFondazione Progetto Ematologia · ITIstituto Nazionale di Statistica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel Cell Carcinoma (MCC) is a highly aggressive neuroendocrine neoplasm of the skin. Due to its rarity, the management of MCC is not standardized across centers. In this article, we present the experience of the Veneto region in the North-East of Italy, where a committee of skin cancer experts has proposed a clinical pathway for the diagnosis and treatment of MCC. Putting together the evidence available in the international literature, we outlined the best approach to the management of patients affected with this malignancy step- by- step for each possible clinical situation. Crucial in this pathway is the role of the multidisciplinary team to deal with the lack of robust information on each aspect of the management of this disease.

Indexed as

Merkel cancerMerkel cell carcinomamultidisciplinary teamnon-melanoma skin cancerstherapeutic and diagnostic pathway

Identifiers

PMID32351898
PMCPMC7174780
OpenAlexW3016515949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.